The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Vulvovaginal Candidiasis Sales Market Report 2024
Synopsis
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
Market Analysis and Insights: Global Drugs for Vulvovaginal Candidiasis Market
The global Drugs for Vulvovaginal Candidiasis market was valued at US$ 816.6 in 2020 and will reach US$ 892.9 million by the end of 2027, growing at a CAGR of 1.5% during 2022-2027.
Global Drugs for Vulvovaginal Candidiasis Scope and Market Size
The global Drugs for Vulvovaginal Candidiasis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Segment by Application
Hospital & Clinic
Pharmacy
The Drugs for Vulvovaginal Candidiasis market is analysed and market size information is provided by regions (countries). Segment by Application, the Drugs for Vulvovaginal Candidiasis market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
Market Analysis and Insights: Global Drugs for Vulvovaginal Candidiasis Market
The global Drugs for Vulvovaginal Candidiasis market was valued at US$ 816.6 in 2020 and will reach US$ 892.9 million by the end of 2027, growing at a CAGR of 1.5% during 2022-2027.
Global Drugs for Vulvovaginal Candidiasis Scope and Market Size
The global Drugs for Vulvovaginal Candidiasis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Miconazole
Clotrimazole
Fluconazole
Econazole
Other
Segment by Application
Hospital & Clinic
Pharmacy
The Drugs for Vulvovaginal Candidiasis market is analysed and market size information is provided by regions (countries). Segment by Application, the Drugs for Vulvovaginal Candidiasis market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Index1 Drugs for Vulvovaginal Candidiasis Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Product Scope
1.2 Drugs for Vulvovaginal Candidiasis Segment by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016 & 2021 & 2027)
1.2.2 Miconazole
1.2.3 Clotrimazole
1.2.4 Fluconazole
1.2.5 Econazole
1.2.6 Other
1.3 Drugs for Vulvovaginal Candidiasis Segment by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts (2016-2027)
1.4.1 Global Drugs for Vulvovaginal Candidiasis Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Drugs for Vulvovaginal Candidiasis Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Drugs for Vulvovaginal Candidiasis Price Trends (2016-2027)
2 Drugs for Vulvovaginal Candidiasis Estimates and Forecasts by Region
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2021)
2.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2021)
2.3 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
2.4.2 Europe Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
2.4.3 China Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
2.4.4 Japan Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
2.4.6 India Drugs for Vulvovaginal Candidiasis Estimates and Projections (2016-2027)
3 Global Drugs for Vulvovaginal Candidiasis Competition Landscape by Players
3.1 Global Top Drugs for Vulvovaginal Candidiasis Players by Sales (2016-2021)
3.2 Global Top Drugs for Vulvovaginal Candidiasis Players by Revenue (2016-2021)
3.3 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2020)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2016-2021)
3.5 Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Drugs for Vulvovaginal Candidiasis Market Size by Type
4.1 Global Drugs for Vulvovaginal Candidiasis Historic Market Review by Type (2016-2021)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2016-2021)
4.1.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2016-2021)
4.2 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2022-2027)
5 Global Drugs for Vulvovaginal Candidiasis Market Size by Application
5.1 Global Drugs for Vulvovaginal Candidiasis Historic Market Review by Application (2016-2021)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2016-2021)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2016-2021)
5.2 Global Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2022-2027)
6 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures
6.1 North America Drugs for Vulvovaginal Candidiasis Sales by Company
6.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
6.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
6.2 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
6.2.1 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
6.2.2 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
6.3 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
6.3.1 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application (2016-2021)
6.3.2 North America Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application (2022-2027)
7 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures
7.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Company
7.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
7.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
7.2 Europe Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
7.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
7.2.2 Europe Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
7.3 Europe Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
7.3.1 Europe 138 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 138 Sales Breakdown by Application (2022-2027)
8 China Drugs for Vulvovaginal Candidiasis Market Facts & Figures
8.1 China Drugs for Vulvovaginal Candidiasis Sales by Company
8.1.1 China Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
8.1.2 China Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
8.2 China Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
8.2.1 China Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
8.2.2 China Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
8.3 China Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
8.3.1 China 245 Sales Breakdown by Application (2016-2021)
8.3.2 China 245 Sales Breakdown by Application (2022-2027)
9 Japan Drugs for Vulvovaginal Candidiasis Market Facts & Figures
9.1 Japan Drugs for Vulvovaginal Candidiasis Sales by Company
9.1.1 Japan Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
9.1.2 Japan Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
9.2 Japan Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
9.2.1 Japan Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
9.2.2 Japan Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
9.3 Japan Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Drugs for Vulvovaginal Candidiasis Market Facts & Figures
10.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Company
10.1.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
10.1.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
10.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
10.2.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India Drugs for Vulvovaginal Candidiasis Market Facts & Figures
11.1 India Drugs for Vulvovaginal Candidiasis Sales by Company
11.1.1 India Drugs for Vulvovaginal Candidiasis Sales by Company (2016-2021)
11.1.2 India Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021)
11.2 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type
11.2.1 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2016-2021)
11.2.2 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Type (2022-2027)
11.3 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application
11.3.1 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application (2016-2021)
11.3.2 India Drugs for Vulvovaginal Candidiasis Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Drugs for Vulvovaginal Candidiasis Business
12.1 Bayer
12.1.1 Bayer Corporation Information
12.1.2 Bayer Business Overview
12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
12.1.5 Bayer Recent Development
12.2 Perrigo
12.2.1 Perrigo Corporation Information
12.2.2 Perrigo Business Overview
12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
12.2.5 Perrigo Recent Development
12.3 J & J
12.3.1 J & J Corporation Information
12.3.2 J & J Business Overview
12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.3.4 J & J Drugs for Vulvovaginal Candidiasis Products Offered
12.3.5 J & J Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Business Overview
12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
12.4.5 Pfizer Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Corporation Information
12.5.2 Bristol-Myers Squibb Business Overview
12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Effik
12.6.1 Effik Corporation Information
12.6.2 Effik Business Overview
12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Effik Drugs for Vulvovaginal Candidiasis Products Offered
12.6.5 Effik Recent Development
12.7 Teva
12.7.1 Teva Corporation Information
12.7.2 Teva Business Overview
12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Teva Drugs for Vulvovaginal Candidiasis Products Offered
12.7.5 Teva Recent Development
12.8 Sanofi
12.8.1 Sanofi Corporation Information
12.8.2 Sanofi Business Overview
12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
12.8.5 Sanofi Recent Development
12.9 Cisen Pharmaceutical
12.9.1 Cisen Pharmaceutical Corporation Information
12.9.2 Cisen Pharmaceutical Business Overview
12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
12.9.5 Cisen Pharmaceutical Recent Development
12.10 Kingyork Group
12.10.1 Kingyork Group Corporation Information
12.10.2 Kingyork Group Business Overview
12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
12.10.5 Kingyork Group Recent Development
13 Drugs for Vulvovaginal Candidiasis Manufacturing Cost Analysis
13.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
13.4 Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Drugs for Vulvovaginal Candidiasis Distributors List
14.3 Drugs for Vulvovaginal Candidiasis Customers
15 Market Dynamics
15.1 Drugs for Vulvovaginal Candidiasis Market Trends
15.2 Drugs for Vulvovaginal Candidiasis Drivers
15.3 Drugs for Vulvovaginal Candidiasis Market Challenges
15.4 Drugs for Vulvovaginal Candidiasis Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
List of TablesList of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Drugs for Vulvovaginal Candidiasis Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Drugs for Vulvovaginal Candidiasis Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Region (2016-2021)
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2021)
Table 6. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Region (2016-2021)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Forecast by Region (2022-2027)
Table 9. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Drugs for Vulvovaginal Candidiasis Revenue Share Forecast by Region (2022-2027)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) of Key Companies (2016-2021)
Table 13. Global Drugs for Vulvovaginal Candidiasis Sales Share by Company (2016-2021)
Table 14. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Company (2016-2021)
Table 16. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2020)
Table 17. Global Drugs for Vulvovaginal Candidiasis Average Price (USD/Unit) of Key Company (2016-2021)
Table 18. Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Sites and Area Served
Table 19. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2016-2021)
Table 22. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2016-2021)
Table 23. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2016-2021)
Table 25. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2022-2027)
Table 26. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2022-2027)
Table 28. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2022-2027)
Table 29. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2016-2021)
Table 30. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2016-2021)
Table 31. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2016-2021)
Table 33. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2022-2027)
Table 34. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2022-2027)
Table 35. Global Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2022-2027)
Table 37. Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2022-2027)
Table 38. North America Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 39. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 40. North America Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 42. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 43. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 44. North America Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 45. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 46. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 47. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 48. North America Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 49. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 50. Europe Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 51. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 52. Europe Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 54. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 55. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 56. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 57. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 58. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 59. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 60. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 61. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 62. China Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 63. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 64. China Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 66. China Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 67. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 68. China Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 69. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 70. China Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 71. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 72. China Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 73. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 74. Japan Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 75. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 76. Japan Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 78. Japan Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 79. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 80. Japan Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 81. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 82. Japan Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 83. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 84. Japan Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 85. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 87. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 91. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 93. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 95. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 97. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 98. India Drugs for Vulvovaginal Candidiasis Sales (K Units) by Company (2016-2021)
Table 99. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2016-2021)
Table 100. India Drugs for Vulvovaginal Candidiasis Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2016-2021)
Table 102. India Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) & (K Units)
Table 103. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Table 104. India Drugs for Vulvovaginal Candidiasis Sales by Type (2022-2027) & (K Units)
Table 105. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2022-2027)
Table 106. India Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) & (K Units)
Table 107. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Table 108. India Drugs for Vulvovaginal Candidiasis Sales by Application (2022-2027) & (K Units)
Table 109. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2022-2027)
Table 110. Bayer Corporation Information
Table 111. Bayer Description and Business Overview
Table 112. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 114. Bayer Recent Development
Table 115. Perrigo Corporation Information
Table 116. Perrigo Description and Business Overview
Table 117. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Perrigo Drugs for Vulvovaginal Candidiasis Product
Table 119. Perrigo Recent Development
Table 120. J & J Corporation Information
Table 121. J & J Description and Business Overview
Table 122. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. J & J Drugs for Vulvovaginal Candidiasis Product
Table 124. J & J Recent Development
Table 125. Pfizer Corporation Information
Table 126. Pfizer Description and Business Overview
Table 127. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 128. Pfizer Drugs for Vulvovaginal Candidiasis Product
Table 129. Pfizer Recent Development
Table 130. Bristol-Myers Squibb Corporation Information
Table 131. Bristol-Myers Squibb Description and Business Overview
Table 132. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 133. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table 134. Bristol-Myers Squibb Recent Development
Table 135. Effik Corporation Information
Table 136. Effik Description and Business Overview
Table 137. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 138. Effik Drugs for Vulvovaginal Candidiasis Product
Table 139. Effik Recent Development
Table 140. Teva Corporation Information
Table 141. Teva Description and Business Overview
Table 142. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 143. Teva Drugs for Vulvovaginal Candidiasis Product
Table 144. Teva Recent Development
Table 145. Sanofi Corporation Information
Table 146. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 147. Sanofi Description and Business Overview
Table 148. Sanofi Drugs for Vulvovaginal Candidiasis Product
Table 149. Sanofi Recent Development
Table 150. Cisen Pharmaceutical Corporation Information
Table 151. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 152. Cisen Pharmaceutical Description and Business Overview
Table 153. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table 154. Cisen Pharmaceutical Recent Development
Table 155. Kingyork Group Corporation Information
Table 156. Kingyork Group Description and Business Overview
Table 157. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2016-2021)
Table 158. Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table 159. Kingyork Group Recent Development
Table 160. Production Base and Market Concentration Rate of Raw Material
Table 161. Key Suppliers of Raw Materials
Table 162. Drugs for Vulvovaginal Candidiasis Distributors List
Table 163. Drugs for Vulvovaginal Candidiasis Customers List
Table 164. Drugs for Vulvovaginal Candidiasis Market Trends
Table 165. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 166. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 167. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2021 & 2027
Figure 6. Hospital & Clinic Examples
Figure 7. Pharmacy Examples
Figure 8. Global Drugs for Vulvovaginal Candidiasis Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2027) & (US$ Million)
Figure 10. Global Drugs for Vulvovaginal Candidiasis Sales (K Units) Growth Rate (2016-2027)
Figure 11. Global Drugs for Vulvovaginal Candidiasis Price Trends Growth Rate (2016-2027) (USD/Unit)
Figure 12. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region: 2016 VS 2021
Figure 13. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region: 2021 VS 2027
Figure 14. North America Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 15. North America Drugs for Vulvovaginal Candidiasis Sales (K Units) Growth Rate (2016-2027)
Figure 16. Europe Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 17. Europe Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2016-2027)
Figure 18. China Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. China Drugs for Vulvovaginal Candidiasis Sales (Million USD) and Growth Rate (2016-2027)
Figure 20. Japan Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. Japan Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2016-2027)
Figure 22. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2016-2027)
Figure 24. India Drugs for Vulvovaginal Candidiasis Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. India Drugs for Vulvovaginal Candidiasis Sales (Million USD) Growth Rate (2016-2027)
Figure 26. Global 5 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue in Drugs for Vulvovaginal Candidiasis: 2016 & 2020
Figure 27. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 28. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2016-2021)
Figure 29. Global Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Type in 2016 & 2020
Figure 30. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2016-2021)
Figure 31. Global Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Application in 2016 & 2020
Figure 32. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 33. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 34. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 35. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 36. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 37. China Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 38. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 39. Japan Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 40. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 41. Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 42. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 43. India Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 44. Key Raw Materials Price Trend
Figure 45. Manufacturing Cost Structure of Drugs for Vulvovaginal Candidiasis
Figure 46. Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure 47. Drugs for Vulvovaginal Candidiasis Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
